If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRDL.L Regulatory News (RDL)

  • There is currently no data for RDL

Response to Oaktree

24 Apr 2018 14:58

RNS Number : 9735L
Ranger Direct Lending Fund PLC
24 April 2018
 

24 April 2018

For immediate release

 

 

Ranger Direct Lending Fund plc

("Ranger" or the "Company")

 

Response to Oaktree

 

The Board notes today that Oaktree Capital Management, L.P. ("Oaktree"). has publicly released private correspondence between itself and the Board of Ranger.

 

On 29 January 2018 the Company announced that an independent committee of the Board was conducting a review of the Company's future investment management arrangements and that an Independent Valuer had been appointed to value the Company's portfolio other than the Princeton assets (together, the "Review Process").

 

The Company notes that Oaktree's announcement today merely publishes their letter dated Wednesday 11th April 2018 in which they relayed the "conclusion" that a winding down was the best way forward for the Company. Since the receipt of Oaktree's letter, the Company and its advisors have communicated to Oaktree that all of the relevant issues raised by Oaktree are already being dealt with as part of the Review Process. The only conclusion which can be drawn from this sequence of events is that Oaktree had no serious interest in engaging in the Review Process and their course of action was solely driven by their short-term considerations.

 

With the Review Process completed on schedule, the Board is now engaged in an active and positive discussion with shareholders regarding the future of the Company (including addressing the issues raised in the Oaktree announcement), ahead of the publication of the findings. It is essential to the future of Ranger as a successful public company to achieve sufficient consensus between the Board and shareholders on the Company's future direction. To deliver this outcome requires a detailed and measured dialogue with shareholders.

 

The Company has obligations to its ZDP shareholders. Oaktree's announcement today offers no detail on how those obligations would be met. During a dialogue with Oaktree on 23rd April 2018, in answer to specific requests for information, Oaktree and its advisors were unable to offer the Company any information of substance around a plan for dealing with the contractual rights of the ZDP shareholders or balancing these interests with Ordinary Shareholders.

 

The Review Process has considered the possibility of a full or partial winding down of the Company's activities and returning cash to shareholders. The Board has a duty to act in the interests of all shareholders and, therefore, must seek to achieve the best capital value for the Company's assets and protect dividend flows. In the view of the Board, Oaktree's approach will accomplish neither of those objectives and lead to an extended period of uncertainty for shareholders. In respect of capital value and dividend flows the Board reiterates its view that Oaktree's approach is driven by its own short-term interests.

 

As noted above, the Board's findings on the Review Process including manager selection and investment policy and the independent valuation of the portfolio (other than the Princeton assets) will be published shortly.

 

Contacts:

 

Ranger Direct Lending Fund plc

Christopher Waldron (Chairman)

 

Via Kinmont

Kinmont

Gavin Kelly

 

Tel: +44 (0)20 7087 9134

 

Liberum

Joshua Hughes

 

Tel: +44 (0)20 3100 2000

Redleaf (for media enquiries)

Robin Tozer

Tel: + 44 (0) 20 3757 6867

ranger@redleafpr.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RSPFKQDPNBKDQQB
Date   Source Headline
3rd Nov 20173:45 pmRNSNet Asset Value(s)
3rd Nov 20173:45 pmRNSMonthly Update
1st Nov 20177:00 amRNSStrategic Partner Discussions
23rd Oct 20172:14 pmRNSPortfolio Update
9th Oct 20174:35 pmRNSMonthly Update
9th Oct 20174:34 pmRNSNet Asset Value(s)
26th Sep 20177:00 amRNSHalf-year Report
15th Sep 20174:35 pmRNSPrice Monitoring Extension
13th Sep 20174:34 pmRNSMonthly Update
13th Sep 20174:32 pmRNSNet Asset Value(s)
14th Aug 20174:05 pmRNSHolding(s) in Company
11th Aug 20173:17 pmRNSDividend Declaration
9th Aug 20172:43 pmRNSHolding(s) in Company
8th Aug 20174:47 pmRNSHolding(s) in Company
7th Aug 20172:40 pmRNSHolding(s) in Company
4th Aug 20178:45 amRNSMonthly Update
4th Aug 20178:45 amRNSNet Asset Value(s)
31st Jul 20174:33 pmRNSHolding(s) in Company
26th Jul 20172:56 pmRNSDirector/PDMR Shareholding
12th Jul 20173:19 pmRNSHolding(s) in Company
12th Jul 20173:19 pmRNSHolding(s) in Company
30th Jun 20173:09 pmRNSMonthly Update
30th Jun 20173:07 pmRNSNet Asset Value(s)
29th Jun 20173:51 pmRNSHolding(s) in Company
28th Jun 20173:43 pmRNSHolding(s) in Company
26th Jun 20174:01 pmRNSDirector/PDMR Shareholding
26th Jun 20174:01 pmRNSDirector/PDMR Shareholding
26th Jun 20177:00 amRNSCorporate Update
22nd Jun 20174:59 pmRNSDirector/PDMR Shareholding
22nd Jun 20173:05 pmRNSDirector/PDMR Shareholding
16th Jun 20175:05 pmRNSDirector/PDMR Shareholding
16th Jun 20174:25 pmRNSDirector/PDMR Shareholding
16th Jun 20174:20 pmRNSDividend Declaration
15th Jun 20175:19 pmRNSDirector/PDMR Shareholding
15th Jun 20175:07 pmRNSResult of AGM
15th Jun 20177:00 amRNSCorporate Update
2nd Jun 20173:39 pmRNSPublication of a Supplementary Prospectus
26th May 20175:35 pmRNSMonthly Update
26th May 20175:28 pmRNSNet Asset Value(s)
23rd May 20175:34 pmRNSDirector/PDMR Shareholding
18th May 20174:13 pmRNSHolding(s) in Company
17th May 20172:29 pmRNSPortfolio Update
15th May 20172:18 pmRNSMonthly Update
12th May 20177:00 amRNSNet Asset Value(s)
2nd May 20174:38 pmRNSTotal Voting Rights
28th Apr 20174:15 pmRNSAnnual Financial Report
12th Apr 20177:00 amRNSPortfolio update - Argon Credit
7th Apr 20172:47 pmRNSDirector/PDMR Shareholding
7th Apr 20177:00 amRNSAdmission to the Official List
31st Mar 20174:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.